Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

There is an urgent need for antiviral agents that treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs against OC43, a human beta coronavirus that causes the common cold, and evaluated the top hits against SARS-CoV-2. Twent...

Descripción completa

Detalles Bibliográficos
Autores principales: Drayman, Nir, DeMarco, Jennifer K., Jones, Krysten A., Azizi, Saara-Anne, Froggatt, Heather M., Tan, Kemin, Maltseva, Natalia Ivanovna, Chen, Siquan, Nicolaescu, Vlad, Dvorkin, Steve, Furlong, Kevin, Kathayat, Rahul S., Firpo, Mason R., Mastrodomenico, Vincent, Bruce, Emily A., Schmidt, Madaline M., Jedrzejczak, Robert, Muñoz-Alía, Miguel Á., Schuster, Brooke, Nair, Vishnu, Han, Kyu-yeon, O’Brien, Amornrat, Tomatsidou, Anastasia, Meyer, Bjoern, Vignuzzi, Marco, Missiakas, Dominique, Botten, Jason W., Brooke, Christopher B., Lee, Hyun, Baker, Susan C., Mounce, Bryan C., Heaton, Nicholas S., Severson, William E., Palmer, Kenneth E., Dickinson, Bryan C., Joachimiak, Andrzej, Randall, Glenn, Tay, Savaş
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809056/
https://www.ncbi.nlm.nih.gov/pubmed/34285133
http://dx.doi.org/10.1126/science.abg5827

Ejemplares similares

Ejemplares similares